AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03263806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SOC Group Management
Description: Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
Study NCT04030195 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR20A
Description: Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied.
Study NCT04030195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
Study NCT04030195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
Study NCT02391805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
Study NCT02391805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6864018
Description: Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
Study NCT02391805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.
Study NCT02391805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.
Study NCT02109029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered IV
Study NCT02109029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin
Description: Administered IV
Study NCT03237091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bihemispheric transcranial pulsed current stimulation (tPCS)
Description: Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
Study NCT01575912 — intervention group
Intervention type: OTHER
Intervention: experimental pain tests
Study NCT01228773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored web-based care program (Health Navigation®)
Description: When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
Study NCT01228773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored web-based care program (Health Navigation®)
Description: When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
Study NCT03783156 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hot snare
Description: polypectomy with hot snare
Study NCT03783156 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cold snare
Description: polypectomy with cold snare
Study NCT04203173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FINANCE-DM
Description: The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
Study NCT01319162 — intervention group
Intervention type: OTHER
Intervention: Weight reduction regimen
Description: The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
Study NCT04798144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distilled water irrigation kept at 2.5°C degree
Description: The use of cold distilled water for final irrigation of root canal system during root canal treatment
Study NCT04798144 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water irrigation kept at room temperature
Description: The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
Study NCT02875769 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dental prophylaxis
Description: Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
Study NCT02875769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis
Description: Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
Study NCT02875769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Description: Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
Study NCT02875769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash CPC+Zn+F
Description: The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
Study NCT02875769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash CHX
Description: The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
Study NCT02875769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No rinsing
Description: The volunteer did not rinse with any pre-procedural mothwash.
Study NCT02875769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
Study NCT00620074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
Study NCT00620074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin
Description: Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
Study NCT04678141 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)
Description: compomer (Dyract XP,R\&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
Study NCT04875117 — intervention group
Intervention type: DEVICE
Intervention: Hearing aid
Description: One or two behind the ear hearing aids provided by the UK National Health Service.
Study NCT01802320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01802320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01802320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02262611 — intervention group
Intervention type: DRUG
Intervention: MicardisPlus®
Study NCT04390256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clove water extract
Description: natural product
Study NCT04390256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clove water extract
Description: natural product
Study NCT04390256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbopol
Description: Bioadhesive polymer
Study NCT04390256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbopol
Description: Bioadhesive polymer
Study NCT04390256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxymethyle cellulose
Description: Bioadhesive polymer
Study NCT04390256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethyle cellulose
Description: Bioadhesive polymer
Study NCT01350908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: 30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
Study NCT01631331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given PO
Study NCT01631331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mohs surgery
Description: Undergo Mohs surgery
Study NCT00670761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
Study NCT00670761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MVA
Description: comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
Study NCT03266393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: Once daily sustained-release tacrolimus
Study NCT03266393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Twice daily immediate-release tacrolimus
Study NCT00164463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg po qd 5/7 days per week
Study NCT00164463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: isoniazid 300 mg po qd 5/7 days per week
Study NCT03588923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH229
Description: tablet, oral, 400 mg once daily for 3 days
Study NCT03588923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: tablet, oral, once daily for 3 days
Study NCT03588923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH229
Description: tablet, oral, 600 mg once daily for 3 days
Study NCT03588923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH229
Description: tablet, oral, 800 mg once daily for 3 days
Study NCT00908128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg Tablet
Study NCT00908128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept®
Description: CellCept® Tablets, 500 mg
Study NCT03077880 — intervention group
Intervention type: PROCEDURE
Intervention: intra-operatory measurement during implant placement
Description: mucoperiosteal flap, soft tissue thickness measurement, implant insertion
Study NCT02517294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parker flex-tip nasotracheal tube
Description: specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
Study NCT02517294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard nasotracheal tube
Description: standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
Study NCT03113708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium
Description: Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
Study NCT03113708 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Heparin Sodium
Description: Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
Study NCT00649987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate Extended-Release Tablets 8 mg
Description: 8mg, single dose fed
Study NCT00649987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VoSpire® ER Tablets 8 mg
Description: 8mg, single dose fed
Study NCT03967938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Capsule
Description: Olaparib tablets 300mg twice daily
Study NCT03948100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Undergo dyadic education program
Study NCT03948100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03948100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03948100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03948100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03948100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Undergo dyadic yoga
Study NCT00268879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Renzapride
Description: Placebo Renzapride 4 mg QD Renzapride 2 mg BID
Study NCT00268879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renzapride
Description: Placebo Renzapride 4 mg QD Renzapride 2 mg BID
Study NCT04677075 — intervention group
Intervention type: PROCEDURE
Intervention: mastectomy
Description: mastectomy either simple or modified radical
Study NCT02350231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The progesterone vaginal pessary
Description: Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
Study NCT02350231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tonics group
Description: Those patients will receive only tonics
Study NCT01058668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study NCT01058668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
Study NCT01601158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood administration
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
Study NCT01601158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
Study NCT04443907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTQ923
Description: Single intravenous infusion of OTQ923 cell suspension
Study NCT04443907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTQ923
Description: Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis
Study NCT01463423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 25 Gray in 1 fraction for small peripheral tumors
Description: Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.
Study NCT01463423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium peripheral tumors
Description: Radiotherapy procedure for participants with medium peripheral tumors > 10 cc and ≤ 30 cc.
Study NCT03304314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: objective chromatic multifocal pupillometer
Description: objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
Study NCT01463423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 54 Gray in 3 fractions for large peripheral tumors
Description: Radiotherapy procedure for participants with large peripheral tumors > 30 cc.
Study NCT04308889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
Study NCT01463423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 40 Gray in 4 fractions for small central tumors
Description: Radiotherapy procedure for participants with small central tumors ≤ 10 cc.
Study NCT01463423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium central tumors
Description: Radiotherapy procedure for participants with medium central tumors > 10 cc and ≤ 30 cc.
Study NCT01463423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 60 Gray in 8 fractions for large central tumors
Description: Radiotherapy procedure for participants with large central tumors > 30 cc.
Study NCT02141919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy
Description: Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
Study NCT01030328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sugar pills by mouth once a day.
Study NCT01030328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TriLipix
Description: 135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
Study NCT04308889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharone
Description: Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.
Study NCT04308889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cantharone
Description: Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.